Advances in the Management of Classical Hodgkin Lymphoma

Abstract

The development of brentuximab vedotin, nivolumab, and pembrolizumab has revolutionized the treatment of classical Hodgkin lymphoma. Continuous efforts are underway to improve the established early-line treatment regimens, incorporating these novel systemic therapies as either replacements for or additions to conventional agents. Although brentuximab vedotin, nivolumab, and pembrolizumab have demonstrated efficacy both as monotherapies and in combinations, critical questions remain regarding the sequencing of these agents, as well as the role of radiation therapy and interim PET scans.